by Yeung Shing On. / Thesis (M.Phil.)--Chinese University of Hong Kong, 1989 / Bibliography: leaves 91-112.

by Wong Yee Wah. / Thesis (M.Ph.)--Chinese University of Hong Kong, 1987. / Bibliography: leaves 130-148.

by Tam Chi Hang, Frankie. / "August 2000." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2000. / Includes bibliographical references (p. 162-174). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Mode of access: World Wide Web. / Abstracts in English and Chinese.

Cancer is a highly complex disease that evolved in response to a wide range of biological and molecular changes that impact disease behaviour, treatment efficacy and clinical outcomes. Studying this diversity in human tumours is essential for gaining insights that will ultimately improve the survival rates of cancer patients. Cancer stem-like cells (CSCs) are believed to be responsible for invasive and metastatic features in tumours and can contribute to chemotherapy resistance and subsequent tumour relapses. There is an increasing need to identify the molecular mechanisms involved in tumour cells, particularly in CSCs. Cancer testis antigens (CTAs) are a subclass of germline proteins normally produced in immune-privileged sites, such as the testis, ovary and placenta of somatic tissues, and the presence of these antigens is increased in a variety of cancers. These characteristics make CTAs highly important immunotherapeutic targets, since they do not harness the immune response in the testes but encode immunogenic proteins that can induce a specific response in cancerous tissues. CTA genes are potentially very importance in clinical applications, including cancer diagnosis, vaccination and immunotherapy. This current study focused on the investigation of two CTAs, TDRD12 and LKAAEAR1, that may have an enhanced presence in cancer and the potential to be immunogenic. TDRD12 is linked to stemness features and enables the proliferation of germ line tumour cells. It appears to act as a possible transcriptional regulator for germline factors that are essential to cell cycle proliferation, germ cell maintenance and stem marker expression. TDRD12 may have the potential to drive oncogenesis and CSC targets. LKAAEAR1 was validated as a CTA at the protein level, showing its production was restricted to germ cells and the central nervous system from normal tissues and showed aberrant production in a wide range of tumours. This protein has been shown to be produced in germ cells undergoing spermatogenesis with strong nuclei staining, suggesting its potential role in this process. LKAAEAR1 potentially acts as a regulator for transposable elements, thereby increasing its contributions to cancer development. This study demonstrated that LKAAEAR1 could potentially be used as a cancer biomarker and therapeutic target.

No description available.

Bibliography: leaves 326-351. / xv, 351 leaves : / Title page, contents and abstract only. The complete thesis in print form is available from the University Library. / Examines the relationship between antigen specific polymeric IgA (pIgA) antibody in serum and intestinal IgA antibody in humans. / Thesis (M.D.)--University of Adelaide, Dept. of Medicine, 1992

"February 1977." Includes bibliographical references (leaves [105]-[120]) The malignant transformation, and the relevance of developmental antigens to the cancer process, is broadly reviewed. The two developmental antigens - foetal and placental - are then examined in experimental mouse and rat tumour systems.

Thesis (Ph.D.) -- University of Adelaide, School of Molecular and Biomedical Science, Discipline of Microbiology and Immunology, 2008. / Includes "Thesis Amendments" attached to the inside back pages. "October 2007" Bibliography: leaves 108-121. Also available in print form.

Thesis (Ph. D.)--University of Washington, 2001. / Vita. Includes bibliographical references (leaves 172-200).

Thesis (Ph. D.)--University of Missouri--Columbia, 2002. / "May 2002." Typescript. Vita. Includes bibliographical references (leaves 237-245).